The prevalent predicament of relapsed acute myeloid leukemia.

38Citations
Citations of this article
78Readers
Mendeley users who have this article in their library.

Abstract

A majority of patients with acute myeloid leukemia (AML) will relapse after achieving complete remission. At relapse, patients should be risk stratified and a decision made about the appropriateness of intensive therapy and whether a potentially curative allogeneic stem cell transplantation (allo-SCT) is possible. Risk factors include duration of first complete remission and adverse cytogenetics, as well as age and FLT3 mutation status. Available therapies are steadily increasing, but for the most part should be regarded as either best palliation or as a bridge to allo-SCT. Simple symptomatic therapies for patients with extreme age or the worst prognosis should also be considered. Newer therapeutic options include novel cytotoxic chemotherapies including clofarabine, immunomodulatory agents, targeted therapies against FLT3 and mTOR, and immunoconjugates. All patients with relapsed AML should be considered for an appropriate clinical trial.

Cite

CITATION STYLE

APA

Szer, J. (2012). The prevalent predicament of relapsed acute myeloid leukemia. Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program. https://doi.org/10.1182/asheducation.v2012.1.43.3798183

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free